CN102112600A - 自然杀伤细胞的增殖方法 - Google Patents
自然杀伤细胞的增殖方法 Download PDFInfo
- Publication number
- CN102112600A CN102112600A CN2009801301215A CN200980130121A CN102112600A CN 102112600 A CN102112600 A CN 102112600A CN 2009801301215 A CN2009801301215 A CN 2009801301215A CN 200980130121 A CN200980130121 A CN 200980130121A CN 102112600 A CN102112600 A CN 102112600A
- Authority
- CN
- China
- Prior art keywords
- cell
- natural killer
- killer cell
- peripheral blood
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 125
- 238000000034 method Methods 0.000 title claims abstract description 58
- 102000015696 Interleukins Human genes 0.000 claims abstract description 22
- 108010063738 Interleukins Proteins 0.000 claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims description 122
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 34
- 108010002350 Interleukin-2 Proteins 0.000 claims description 28
- 102000000588 Interleukin-2 Human genes 0.000 claims description 28
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 235000015097 nutrients Nutrition 0.000 claims description 9
- 230000002779 inactivation Effects 0.000 claims description 8
- 229940127174 UCHT1 Drugs 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 abstract description 7
- 239000011886 peripheral blood Substances 0.000 abstract description 7
- 238000012258 culturing Methods 0.000 abstract description 3
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 239000012930 cell culture fluid Substances 0.000 description 22
- 238000005119 centrifugation Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- 230000004663 cell proliferation Effects 0.000 description 10
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 239000012636 effector Substances 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000013016 damping Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004332 phalangeal cell Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Abstract
Description
Claims (12)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2008-0074069 | 2008-07-29 | ||
KR1020080074069A KR101133185B1 (ko) | 2008-07-29 | 2008-07-29 | 자연살해세포의 증식방법 |
PCT/KR2009/004228 WO2010013947A2 (ko) | 2008-07-29 | 2009-07-29 | 자연살해세포의 증식방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102112600A true CN102112600A (zh) | 2011-06-29 |
CN102112600B CN102112600B (zh) | 2014-09-17 |
Family
ID=41610847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980130121.5A Active CN102112600B (zh) | 2008-07-29 | 2009-07-29 | 自然杀伤细胞的增殖方法 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP5358683B2 (zh) |
KR (1) | KR101133185B1 (zh) |
CN (1) | CN102112600B (zh) |
WO (1) | WO2010013947A2 (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103923879A (zh) * | 2014-04-29 | 2014-07-16 | 湖北华赛生物医药技术有限公司 | 一种nk细胞因子混合物的制备方法及其应用 |
CN104204194A (zh) * | 2011-12-22 | 2014-12-10 | 财团法人牧岩生命工学研究所 | 生产自然杀伤细胞的方法、由该方法生产的自然杀伤细胞以及包含该自然杀伤细胞的用于治疗癌症和感染性疾病的组合物 |
CN104593324A (zh) * | 2014-11-28 | 2015-05-06 | 广州赛莱拉干细胞科技股份有限公司 | 一种自然杀伤细胞的培养基及自然杀伤细胞的扩增培养方法 |
CN105441390A (zh) * | 2015-11-18 | 2016-03-30 | 深圳爱生再生医学科技有限公司 | Nk细胞的体外三维扩增培养方法 |
CN106148282A (zh) * | 2016-07-29 | 2016-11-23 | 北京时合生物科技有限公司 | 一种自然杀伤细胞的培养方法 |
CN106434554A (zh) * | 2016-08-31 | 2017-02-22 | 北京同立海源生物科技有限公司 | Nk细胞的制备方法 |
CN107002039A (zh) * | 2014-11-26 | 2017-08-01 | Gc细胞治疗 | 使用t细胞用于培养自然杀伤细胞的方法 |
CN108004210A (zh) * | 2017-12-18 | 2018-05-08 | 吉林大学 | 一种大量诱导扩增具有adcc效应的nk细胞的方法 |
CN109810944A (zh) * | 2019-01-24 | 2019-05-28 | 安徽瑞达健康产业有限公司 | 一种体外稳定扩增高纯度、高细胞毒活性nk细胞的方法 |
CN113544262A (zh) * | 2019-05-16 | 2021-10-22 | 格林克塞尔 | 包括细胞因子诱导的杀伤细胞的活化淋巴细胞及其制备方法 |
CN113832101A (zh) * | 2021-09-03 | 2021-12-24 | 秦红 | 自然杀伤细胞体外高效扩增的制备方法 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ599825A (en) | 2007-09-28 | 2014-10-31 | Anthrogenesis Corp | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
CN107760648A (zh) | 2010-07-13 | 2018-03-06 | 人类起源公司 | 产生自然杀伤细胞的方法、由此获得的细胞群体及其用途 |
KR101039843B1 (ko) * | 2010-08-30 | 2011-06-09 | 주식회사 엔케이바이오 | 자기활성화 림프구 배양용 배지 조성물 및 이를 이용한 자기활성화 림프구 배양방법 |
KR101121101B1 (ko) * | 2010-09-08 | 2012-03-20 | 고려대학교 산학협력단 | 클러스테린을 포함하는 자연살상 세포 증식 촉진용 조성물 |
TWI439275B (zh) * | 2010-12-31 | 2014-06-01 | Glory Biomedical Co Ltd | 一種人類自然殺手細胞之體外增殖方法 |
JPWO2012099093A1 (ja) * | 2011-01-21 | 2014-06-30 | 株式会社日本バイオセラピー研究所 | Nk細胞強化型血液製剤の製造方法 |
JP5572863B2 (ja) | 2011-06-24 | 2014-08-20 | 国立大学法人九州大学 | Nk細胞の増幅方法 |
JP5840876B2 (ja) * | 2011-06-24 | 2016-01-06 | テラ株式会社 | Nk細胞を増幅するための組成物及び方法 |
CN102839153A (zh) * | 2012-09-13 | 2012-12-26 | 济南泰生生物技术有限公司 | 一种以cd3+cd8+为主的活化淋巴细胞的扩增、冻存及复苏方法 |
KR101923848B1 (ko) | 2013-01-15 | 2018-11-29 | 히로유키 아베 | 면역세포 함유 조성물의 제조방법 및 암 치료용 조성물 |
CN115282165A (zh) | 2013-02-05 | 2022-11-04 | 细胞结构公司 | 来自胎盘的自然杀伤细胞 |
JP6588465B2 (ja) * | 2014-01-03 | 2019-10-09 | アカデミア シニカAcademia Sinica | 修飾ナチュラルキラー細胞、その組成物および用途 |
WO2016122014A1 (ko) * | 2015-01-27 | 2016-08-04 | 한국생명공학연구원 | 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도 |
KR101909879B1 (ko) * | 2015-06-24 | 2018-10-19 | 주식회사 차바이오텍 | 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물 |
WO2016209021A1 (ko) * | 2015-06-24 | 2016-12-29 | 주식회사 차바이오텍 | 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물 |
US10300089B2 (en) * | 2016-11-08 | 2019-05-28 | University Of Central Florida Research Foundation, Inc. | Methods for high scale therapeutic production of memory NK cells |
KR101969045B1 (ko) * | 2016-11-22 | 2019-04-19 | 신동혁 | 면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물 |
CN107541491A (zh) * | 2017-10-12 | 2018-01-05 | 广州金晟生物科技有限公司 | 一种nk细胞体外培养方法 |
IL276365B2 (en) | 2018-02-01 | 2023-10-01 | Nkmax Co Ltd | A method for the production of natural killer cells and a preparation for cancer treatment |
WO2019182392A1 (ko) * | 2018-03-23 | 2019-09-26 | 주식회사 녹십자랩셀 | 자연살해세포의 제조방법 |
KR102232321B1 (ko) * | 2018-03-23 | 2021-03-26 | 주식회사 녹십자랩셀 | 자연살해세포의 제조방법 |
EP3884041A2 (en) * | 2018-11-21 | 2021-09-29 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (nk) cell subset and related compositions and methods |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0409655A2 (en) * | 1989-07-21 | 1991-01-23 | Ortho Pharmaceutical Corporation | Method for stimulating proliferation of peripheral blood lymphocytes |
US20030068306A1 (en) * | 2001-09-14 | 2003-04-10 | Dilber Mehmet Sirac | Medium |
WO2008023874A1 (en) * | 2006-08-23 | 2008-02-28 | Binex Co., Ltd. | Manufacturing method of activated lymphocytes for immunotherapy |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2186685T3 (es) * | 1993-04-06 | 2003-05-16 | Targeted Genetics Corp | Genes hibridos destinados para ser utilizados en la produccion de celulas t citotoxicas independientes de celulas t auxiliares. |
US5827642A (en) * | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
WO2004056392A1 (en) * | 2002-12-23 | 2004-07-08 | Innate Pharma | Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same |
JP2005139118A (ja) * | 2003-11-07 | 2005-06-02 | Ortho Mcneil Pharmaceut Inc | 腫瘍の治療のための細胞治療方法 |
-
2008
- 2008-07-29 KR KR1020080074069A patent/KR101133185B1/ko active IP Right Grant
-
2009
- 2009-07-29 JP JP2011521023A patent/JP5358683B2/ja active Active
- 2009-07-29 CN CN200980130121.5A patent/CN102112600B/zh active Active
- 2009-07-29 WO PCT/KR2009/004228 patent/WO2010013947A2/ko active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0409655A2 (en) * | 1989-07-21 | 1991-01-23 | Ortho Pharmaceutical Corporation | Method for stimulating proliferation of peripheral blood lymphocytes |
US20030068306A1 (en) * | 2001-09-14 | 2003-04-10 | Dilber Mehmet Sirac | Medium |
WO2008023874A1 (en) * | 2006-08-23 | 2008-02-28 | Binex Co., Ltd. | Manufacturing method of activated lymphocytes for immunotherapy |
Non-Patent Citations (2)
Title |
---|
JÜRGEN LUHM ET AL: "Large-scale generation of natural killer lymphocytes for clinical application", 《JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH》 * |
OCHOA AC ET AL: "Long-term growth of lymphokine-activated killer (LAK)cells:role of anti-CD3,beta-IL1,interferon-gamma and-beta", 《J IMMUNOL》 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104204194A (zh) * | 2011-12-22 | 2014-12-10 | 财团法人牧岩生命工学研究所 | 生产自然杀伤细胞的方法、由该方法生产的自然杀伤细胞以及包含该自然杀伤细胞的用于治疗癌症和感染性疾病的组合物 |
CN104204194B (zh) * | 2011-12-22 | 2018-08-03 | 财团法人牧岩生命工学研究所 | 生产自然杀伤细胞的方法、由该方法生产的自然杀伤细胞以及包含该自然杀伤细胞的用于治疗癌症和感染性疾病的组合物 |
CN103923879B (zh) * | 2014-04-29 | 2016-03-30 | 湖北华赛生物医药技术有限公司 | 一种nk细胞因子混合物的制备方法及其应用 |
CN103923879A (zh) * | 2014-04-29 | 2014-07-16 | 湖北华赛生物医药技术有限公司 | 一种nk细胞因子混合物的制备方法及其应用 |
CN107002039A (zh) * | 2014-11-26 | 2017-08-01 | Gc细胞治疗 | 使用t细胞用于培养自然杀伤细胞的方法 |
US11766456B2 (en) | 2014-11-26 | 2023-09-26 | GC Cell Corporation | Method for culturing natural killer cells using T cells |
CN107002039B (zh) * | 2014-11-26 | 2021-04-23 | Gc细胞治疗 | 使用t细胞用于培养自然杀伤细胞的方法 |
CN104593324B (zh) * | 2014-11-28 | 2018-04-13 | 广州赛莱拉干细胞科技股份有限公司 | 一种自然杀伤细胞的培养基及自然杀伤细胞的扩增培养方法 |
CN104593324A (zh) * | 2014-11-28 | 2015-05-06 | 广州赛莱拉干细胞科技股份有限公司 | 一种自然杀伤细胞的培养基及自然杀伤细胞的扩增培养方法 |
CN105441390A (zh) * | 2015-11-18 | 2016-03-30 | 深圳爱生再生医学科技有限公司 | Nk细胞的体外三维扩增培养方法 |
CN106148282A (zh) * | 2016-07-29 | 2016-11-23 | 北京时合生物科技有限公司 | 一种自然杀伤细胞的培养方法 |
CN106434554A (zh) * | 2016-08-31 | 2017-02-22 | 北京同立海源生物科技有限公司 | Nk细胞的制备方法 |
CN106434554B (zh) * | 2016-08-31 | 2019-07-26 | 北京同立海源生物科技有限公司 | Nk细胞的制备方法 |
CN108004210A (zh) * | 2017-12-18 | 2018-05-08 | 吉林大学 | 一种大量诱导扩增具有adcc效应的nk细胞的方法 |
CN108004210B (zh) * | 2017-12-18 | 2020-09-04 | 吉林省吉恩致合生物治疗技术有限公司 | 一种大量诱导扩增具有adcc效应的nk细胞的方法 |
CN109810944A (zh) * | 2019-01-24 | 2019-05-28 | 安徽瑞达健康产业有限公司 | 一种体外稳定扩增高纯度、高细胞毒活性nk细胞的方法 |
CN113544262A (zh) * | 2019-05-16 | 2021-10-22 | 格林克塞尔 | 包括细胞因子诱导的杀伤细胞的活化淋巴细胞及其制备方法 |
CN113832101A (zh) * | 2021-09-03 | 2021-12-24 | 秦红 | 自然杀伤细胞体外高效扩增的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2011529341A (ja) | 2011-12-08 |
KR101133185B1 (ko) | 2012-04-06 |
WO2010013947A2 (ko) | 2010-02-04 |
CN102112600B (zh) | 2014-09-17 |
JP5358683B2 (ja) | 2013-12-04 |
KR20100012586A (ko) | 2010-02-08 |
WO2010013947A3 (ko) | 2010-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102112600B (zh) | 自然杀伤细胞的增殖方法 | |
CN107326008B (zh) | 一种从外周血中高效高纯度扩增自然杀伤细胞的方法 | |
Sakamoto et al. | Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer | |
US20180223257A1 (en) | Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells | |
JP6010136B2 (ja) | ナチュラルキラー細胞の製造方法、その方法により製造されたナチュラルキラー細胞、並びにそれを含む腫瘍及び感染性疾患治療用組成物 | |
AU2015354941B2 (en) | Method for culturing natural killer cells using T cells | |
CN106574244A (zh) | 用细胞因子组合物扩增淋巴细胞用于主动细胞免疫治疗 | |
CN101273122A (zh) | 普通γ链细胞因子在记忆T淋巴细胞的显影、分离和遗传修饰中的应用 | |
CN105925527A (zh) | 一种用于制备nk细胞的试剂盒及其应用方法 | |
CN108588022A (zh) | 体外培养富集人cd4+和cd8+ tcm细胞的方法 | |
CN107847585A (zh) | 用于得到体内存留性和治疗活性的nkt细胞亚群以及其繁殖 | |
JP3619853B2 (ja) | ナチュラルキラー細胞の増殖方法 | |
WO2015014291A1 (zh) | 通过无血清培养扩增活化淋巴细胞的方法 | |
CN104894072A (zh) | 一种自体自然杀伤细胞增殖的制备方法及其应用 | |
US20210147803A1 (en) | Method for producing natural killer cells | |
CN109266607A (zh) | 一种优化的临床用tcm分选、诱导培养和质量控制鉴定试剂盒及应用 | |
WO2022130015A2 (en) | Processing of tumor infiltrating lymphocytes | |
CN108192865B (zh) | Nk细胞体外扩增方法及用于该方法的试剂盒 | |
Lee et al. | Monocyte-derived dendritic cells from HLA-matched allogeneic donors showed a greater ability to induce leukemic cell-specific T cells in comparison to leukemic cell-derived dendritic cells or monocyte-derived dendritic cells from AML patients | |
CN108441473A (zh) | 一种体外富集cd8+* t细胞的方法 | |
Itoh et al. | Bulk cultures of canine peripheral blood lymphocytes with solid phase anti-CD3 antibody and recombinant interleukin-2 for use in immunotherapy | |
MX2009001269A (es) | Metodo de proliferacion de celulas asesinas activadas por linfocina. | |
US20240132844A1 (en) | Highly Potent M-CENK Cells And Methods | |
EP1759707A2 (en) | Canine tumor treatment method, pharmaceutical formulation applied thereto and method of cryogenically preserving cells used therewith | |
KR102495647B1 (ko) | 건강한 사람의 면역세포 배양액을 이용한 nk 세포의 함량을 증진시키는 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: GC CELL THERAPY Free format text: FORMER OWNER: RYOKUGUGI K.K. Effective date: 20120203 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20120203 Address after: Gyeonggi Do, South Korea Applicant after: GREEN CROSS LAB CELL CORPORATION Co-applicant after: Seoul Nat University Hospital Address before: Gyeonggi Do, South Korea Applicant before: GREEN CROSS Corp. Co-applicant before: Seoul Nat University Hospital |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |